STX18

Across TCGA pan-cancer cohorts, STX18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STX18 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STX18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STX18 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where STX18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.218	0.792	.003	34	view →
HNSC	DFS	Median	II,III,IV	0.995	0.897	.006	17	view →
PDAC	DFS	Quartile	III,IV	0.979	0.318	.004	10	view →
CCRCC	OS	Quartile	All	1.000	0.845	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STX18–LUAD (DFS)

Open the LUAD breakdown →